Dear Professor,

Re: No. 70245 “Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal NK/T-cell lymphoma: A case report”

Thank you and the reviewers for reviewing our manuscript and giving us the opportunity to revise. Based on your valuable comment and kind suggestions, we have revised the manuscript on the original manuscript. Here, we attached point-to-point reply to the reviewers’ comments.

We hope that the improved manuscript is up to your standard. Thanks again for all your help.

Best regards,

Xiaodong Li
A point-to-point reply

Comments from:
1. There has been a trial evaluating the effects of a PD-L1 antibody plus Chidamide for r/r-ENKTL. A study by Yan Gao et al. conducted from March 2019 to May 2020, evaluated the efficacy of Sintilimab plus Chidamide on 37 ENKTL patients. This drug combination showed effective antitumor activity, and durable response in patients with r/r-ENKTL. (https://doi.org/10.1182/blood-2020-134665). Please be very clear about what your study adds to the existing literature and clearly detail learning points?
   Response: Thanks for the Reviewer’s suggestion. In the revised paper, we have cited the study by Yan Gao and explained the innovation of our study in discussion.

2. Please provide a table on literature review and a comment should be made about this table. In other words, a paragraph should be written about some parameters such as the age, gender, type of treatment, and follow-up period of the patients - The data presented could stand from some fine tuning.
   Response: We acknowledge the Reviewer’s comment. In the revised paper, we added Table 1 on literature review and explained in the discussion.

3. Please proofread the manuscript carefully. -Please cite the CARE 2016 paper above in your text. https://doi.org/10.1016/j.ijsu.2016.08.014
   Response: Thanks for the suggestion sincerely. Many grammatical or typographical mistakes have been revised. We send the revised manuscript to a professional English language editing company and obtained new language certificate. We conducted the manuscript according to the CARE 2016 guidelines.